Romosozumab is a monoclonal antibody that binds and inhibits sclerostin. This increases bone formation and decreases bone resorption
Romosozumab associated with rapid and large reductions in risk of vertebral fracture compared to placebo. The results of a study presented at the Annual European Congress of Rheumatology (EULAR) 2017 press conference showed that, in postmenopausal women with osteoporosis, 12 months treatment with romosozumab was associated with rapid and large reductions in their risk of a vertebral fracture compared to placebo.
In those women receiving romosozumab, all clinical vertebral fractures occurred in the first 2 months of treatment; overall, the risk of a vertebral fracture was more than 5 times greater in the group of women given placebo...
Read More
Recent Comments